Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Gustavo Verdier, BSc, BPharm, MBA

ViiV Healthcare, Montréal, QC, Canada, Canada

Disclosure(s): GlaxoSmithKline: Stocks/Bonds; ViiV Healthcare ULC: Salary

Poster(s):

1252 - A Real-World Observational Study on HIV-Infected Patients who Switched from Nevirapine + 2 Nucleoside Reverse Transcriptase Inhibitors to Dolutegravir/Lamivudine in British Columbia, Canada
Friday, October 21, 2022
12:15 PM – 1:30 PM US ET
1285 - Systematic Literature Review of Real-world Experience with the 2-Drug Regimen Dolutegravir and Lamivudine in People with HIV Who Would Not Have Met Inclusion Criteria for the Phase 3 Clinical Program
Friday, October 21, 2022
12:15 PM – 1:30 PM US ET